Literature DB >> 24403535

Autoimmune vitiligo does not require the ongoing priming of naive CD8 T cells for disease progression or associated protection against melanoma.

Katelyn T Byrne1, Peisheng Zhang, Shannon M Steinberg, Mary Jo Turk.   

Abstract

Vitiligo is a CD8 T cell-mediated autoimmune disease that has been shown to promote the longevity of memory T cell responses to melanoma. However, mechanisms whereby melanocyte/melanoma Ag-specific T cell responses are perpetuated in the context of vitiligo are not well understood. These studies investigate the possible phenomenon of naive T cell priming in hosts with melanoma-initiated, self-perpetuating, autoimmune vitiligo. Using naive pmel (gp10025-33-specific) transgenic CD8 T cells, we demonstrate that autoimmune melanocyte destruction induces naive T cell proliferation in skin-draining lymph nodes, in an Ag-dependent fashion. These pmel T cells upregulate expression of CD44, P-selectin ligand, and granzyme B. However, they do not downregulate CD62L, nor do they acquire the ability to produce IFN-γ, indicating a lack of functional priming. Accordingly, adult thymectomized mice exhibit no reduction in the severity or kinetics of depigmentation or long-lived protection against melanoma, indicating that the continual priming of naive T cells is not required for vitiligo or its associated antitumor immunity. Despite this, depletion of CD4 T cells during the course of vitiligo rescues the priming of naive pmel T cells that are capable of producing IFN-γ and persisting as memory, suggesting an ongoing and dominant mechanism of suppression by regulatory T cells. This work reveals the complex regulation of self-reactive CD8 T cells in vitiligo and demonstrates the overall poorly immunogenic nature of this autoimmune disease setting.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24403535      PMCID: PMC4077353          DOI: 10.4049/jimmunol.1302139

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  30 in total

1.  Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease.

Authors:  Karl S Lang; Mike Recher; Tobias Junt; Alexander A Navarini; Nicola L Harris; Stefan Freigang; Bernhard Odermatt; Curdin Conrad; Lars M Ittner; Stefan Bauer; Sanjiv A Luther; Satoshi Uematsu; Shizuo Akira; Hans Hengartner; Rolf M Zinkernagel
Journal:  Nat Med       Date:  2005-01-16       Impact factor: 53.440

2.  Tissue destruction caused by cytotoxic T lymphocytes induces deletional tolerance.

Authors:  Ian A Parish; Jason Waithman; Gayle M Davey; Gabrielle T Belz; Justine D Mintern; Christian Kurts; Robyn M Sutherland; Francis R Carbone; William R Heath
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-20       Impact factor: 11.205

3.  Autoimmune melanocyte destruction is required for robust CD8+ memory T cell responses to mouse melanoma.

Authors:  Katelyn T Byrne; Anik L Côté; Peisheng Zhang; Shannon M Steinberg; Yanxia Guo; Rameeza Allie; Weijun Zhang; Marc S Ernstoff; Edward J Usherwood; Mary Jo Turk
Journal:  J Clin Invest       Date:  2011-04-11       Impact factor: 14.808

4.  Late priming and variability of epitope-specific CD8+ T cell responses during a persistent virus infection.

Authors:  Christopher C Kemball; Eun D Han Lee; Vaiva Vezys; Thomas C Pearson; Christian P Larsen; Aron E Lukacher
Journal:  J Immunol       Date:  2005-06-15       Impact factor: 5.422

5.  Memory inflation during chronic viral infection is maintained by continuous production of short-lived, functional T cells.

Authors:  Christopher M Snyder; Kathy S Cho; Elizabeth L Bonnett; Serani van Dommelen; Geoffrey R Shellam; Ann B Hill
Journal:  Immunity       Date:  2008-10-17       Impact factor: 31.745

6.  Effective melanoma immunotherapy in mice by the skin-depigmenting agent monobenzone and the adjuvants imiquimod and CpG.

Authors:  Jasper G van den Boorn; Debby Konijnenberg; Esther P M Tjin; Daisy I Picavet; Nico J Meeuwenoord; Dmitri V Filippov; J P Wietze van der Veen; Jan D Bos; Cornelis J M Melief; Rosalie M Luiten
Journal:  PLoS One       Date:  2010-05-13       Impact factor: 3.240

7.  Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study.

Authors:  P Quaglino; F Marenco; S Osella-Abate; N Cappello; M Ortoncelli; B Salomone; M T Fierro; P Savoia; M G Bernengo
Journal:  Ann Oncol       Date:  2009-07-21       Impact factor: 32.976

8.  Tumor-specific Th17-polarized cells eradicate large established melanoma.

Authors:  Pawel Muranski; Andrea Boni; Paul A Antony; Lydie Cassard; Kari R Irvine; Andrew Kaiser; Chrystal M Paulos; Douglas C Palmer; Christopher E Touloukian; Krzysztof Ptak; Luca Gattinoni; Claudia Wrzesinski; Christian S Hinrichs; Keith W Kerstann; Lionel Feigenbaum; Chi-Chao Chan; Nicholas P Restifo
Journal:  Blood       Date:  2008-03-19       Impact factor: 22.113

9.  Selective delivery of beta cell antigen to dendritic cells in vivo leads to deletion and tolerance of autoreactive CD8+ T cells in NOD mice.

Authors:  Arunika Mukhopadhaya; Tadashi Hanafusa; Irene Jarchum; Yi-Guang Chen; Yoshiko Iwai; David V Serreze; Ralph M Steinman; Kristin V Tarbell; Teresa P DiLorenzo
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-22       Impact factor: 11.205

10.  Induction of postsurgical tumor immunity and T-cell memory by a poorly immunogenic tumor.

Authors:  Peisheng Zhang; Anik L Côté; Victor C de Vries; Edward J Usherwood; Mary Jo Turk
Journal:  Cancer Res       Date:  2007-07-01       Impact factor: 12.701

View more
  8 in total

1.  Resident memory T cells in the skin mediate durable immunity to melanoma.

Authors:  Brian T Malik; Katelyn T Byrne; Jennifer L Vella; Peisheng Zhang; Tamer B Shabaneh; Shannon M Steinberg; Aleksey K Molodtsov; Jacob S Bowers; Christina V Angeles; Chrystal M Paulos; Yina H Huang; Mary Jo Turk
Journal:  Sci Immunol       Date:  2017-04-14

2.  Anatomically distinct fibroblast subsets determine skin autoimmune patterns.

Authors:  Zijian Xu; Daoming Chen; Yucheng Hu; Kaiju Jiang; Huanwei Huang; Yingxue Du; Wenbo Wu; Jiawen Wang; Jianhua Sui; Wenhui Wang; Long Zhang; Shuli Li; Chunying Li; Yong Yang; Jianmin Chang; Ting Chen
Journal:  Nature       Date:  2021-12-15       Impact factor: 49.962

3.  Reconstruction of Cell-type-Specific Interactomes at Single-Cell Resolution.

Authors:  Shahin Mohammadi; Jose Davila-Velderrain; Manolis Kellis
Journal:  Cell Syst       Date:  2019-11-27       Impact factor: 10.304

4.  Resident memory CD8+ T cells in regional lymph nodes mediate immunity to metastatic melanoma.

Authors:  Aleksey K Molodtsov; Nikhil Khatwani; Jennifer L Vella; Kathryn A Lewis; Yanding Zhao; Jichang Han; Delaney E Sullivan; Tyler G Searles; Nicholas K Preiss; Tamer B Shabaneh; Peisheng Zhang; Aaron R Hawkes; Brian T Malik; Fred W Kolling; Edward J Usherwood; Sandra L Wong; Joseph D Phillips; Keisuke Shirai; Christina V Angeles; Shaofeng Yan; Tyler J Curiel; Yina H Huang; Chao Cheng; Mary Jo Turk
Journal:  Immunity       Date:  2021-09-14       Impact factor: 43.474

Review 5.  Myron Gordon Award paper: Microbes, T-cell diversity and pigmentation.

Authors:  I Caroline Le Poole
Journal:  Pigment Cell Melanoma Res       Date:  2021-01-27       Impact factor: 4.159

Review 6.  Tissue Resident CD8 Memory T Cell Responses in Cancer and Autoimmunity.

Authors:  Aleksey Molodtsov; Mary Jo Turk
Journal:  Front Immunol       Date:  2018-11-29       Impact factor: 7.561

7.  Identification of the genomic insertion site of Pmel-1 TCR α and β transgenes by next-generation sequencing.

Authors:  Yun Ji; Natalie Abrams; Wei Zhu; Eddie Salinas; Zhiya Yu; Douglas C Palmer; Parthav Jailwala; Zulmarie Franco; Rahul Roychoudhuri; Eric Stahlberg; Luca Gattinoni; Nicholas P Restifo
Journal:  PLoS One       Date:  2014-05-14       Impact factor: 3.240

8.  Autoimmune vitiligo in rheumatic disease in the mestizo Mexican population.

Authors:  Esperanza Avalos-Díaz; Elena Pérez-Pérez; Mayra Rodríguez-Rodríguez; María-Guadalupe Pacheco-Tovar; Rafael Herrera-Esparza
Journal:  Biomed Rep       Date:  2016-06-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.